BioMarin Pharmaceutical Inc. (BMRN) Cash Flow Statement

The operating cash flow to net income ratio swings from -1.53 to 3.76 across recent quarters, which indicates earnings are not a reliable guide to cash generation in the near term. Such volatility may reflect acquisition accounting, integration charges, or timing of receivables rather than underlying operating deterioration. Investors should monitor whether operating cash flow remains positive once integration costs normalize, as the current pattern warrants further investigation rather than firm conclusions.

The wide band of free cash flow margins suggests that the company's cash output depends heavily on working capital timing rather than a stable recurring base. Capital expenditure remains modest at roughly 2 to 5 percent of revenue, so the swings are driven primarily by operating items rather than investment intensity. The recent recovery to a mid-teens margin appears encouraging but does not yet establish a durable trend.

Large and alternating working capital movements suggest that collections from lumpy international government orders may be influencing quarterly cash timing. The pattern makes it difficult to separate underlying cash earnings from timing effects using quarterly data alone. Analysts should consider trailing twelve-month figures to reduce distortion from these swings.

The absence of dividends and limited buybacks suggests management is prioritizing balance sheet use for acquisitions such as Amicus integration. The scale of the Q2 2026 outflow relative to recent operating cash flow raises questions about the return on that deployment that remain unanswered by the data. Returns from these acquisitions may take time to appear in reported cash flows and should be tracked closely.